BridgeBio Oncology Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$145.8M | -$80.9M | -$41,692 |
| Operating expenses | $145.8M | $80.9M | — |
| Cash from operations | -$113.9M | -$55.0M | — |
| Capital expenditure | $606,000 | $49,000 | — |
| Free cash flow | -$114.5M | -$55.1M | — |
| Impairments | $0 | $0 | — |
| Total assets | $448.4M | $164.3M | $332,894 |
| Total liabilities | $37.3M | $19.6M | $396,463 |
Shares outstanding 80.1M · Free float 57.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.